Ying Xin Zhang

Ying Xin Zhang

Auto-generated profile, based on publicly available information

Ying Xin Zhang

Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong , Hong Kong SAR

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2023 in Human Reproduction
Verified
Journal Article
Closed access
PDF file
YLYing Li
Ying Li
MCMatthew Hoi Kin Chau
Matthew Hoi Kin Chau
YZYing Xin Zhang
Ying Xin Zhang
YZYilin Zhao
Yilin Zhao
SXShuwen Xue
Shuwen Xue
PCPui Wah Jacqueline Chung
Pui Wah Jacqueline Chung
STUDY QUESTION: Can multiple-site low-pass genome sequencing (GS) of products of conception (POCs) improve the detection of genetic abnormalities, especially heterogeneously distributed mosaicism and homogeneously distributed mosaicism in first-trimester miscarriage? SUMMARY ANSWER: Multiple-site sampling combined with low-pass GS significantly increased genetic diagnostic yield (77.0%, 127/165) of first-trimester miscarriages, with mosaicisms accounting for 17.0% (28/165), especially heterogeneously distributed mosaicisms (75%, 21/28) that are currently underappreciated. WHAT IS KNOWN ALREADY: Aneuploidies are well known to cause first-trimester miscarriage, which are detectable by conventional karyotyping and next-generation sequencing (NGS) on a single-site sampling basis. However, there are limited studies demonstrating the implications of mosaic genetic abnormalities in first-trimester miscarriages, especially when genetic heterogeneity is present in POCs. STUDY DESIGN, SIZE, DURATION: This is a cross-sectional cohort study carried out at a university-affiliated public hospital. One hundred seventy-four patients diagnosed with first-trimester miscarriage from December 2018 to November 2021 were offered ultrasound-guided manual vacuum aspiration (USG-MVA) treatment. Products of conception were subjected to multiple-site low-pass GS for the detection of chromosomal imbalances. PARTICIPANTS/MATERIALS, SETTING, METHODS: For each POC, multiple sites of villi (three sites on average) were biopsied for low-pass GS. Samples with maternal cell contamination (MCC) and polyploidy were excluded based on the quantitative fluorescence polymerase chain reaction (QF-PCR) results. The spectrum of chromosomal abnormalities, including mosaicism (heterogeneously distributed and homogeneously distributed) and constitutional abnormalities was investigated. Chromosomal microarray analysis and additional DNA fingerprinting were used for validation and MCC exclusion. A cross-platform comparison between conventional karyotyping and our multiple-site approach was also performed. MAIN RESULTS AND THE ROLE OF CHANCE: One hundred sixty-five POCs (corresponding to 490 DNA samples) were subjected to low-pass GS. Genetic abnormalities were detected in 77.0% (127/165) of POCs by our novel approach. Specifically, 17.0% (28/165) of cases had either heterogeneously distributed mosaicism (12.7%, 21/165) or homogeneously distributed mosaicism (6.1%, 10/165) (three cases had both types of mosaicism). The remaining 60.0% (99/165) of cases had constitutional abnormalities. In addition, in the 71 cases with karyotyping performed in parallel, 26.8% (19/71) of the results could be revised by our approach. LIMITATIONS, REASONS FOR CAUTION: Lack of a normal gestational week-matched cohort might hinder the establishment of a causative link between mosaicisms and first-trimester miscarriage. WIDER IMPLICATIONS OF THE FINDINGS: Low-pass GS with multiple-site sampling increased the detection of chromosomal mosaicisms in first-trimester miscarriage POCs. This innovative multiple-site low-pass GS approach enabled the novel discovery of heterogeneously distributed mosaicism, which was prevalent in first-trimester miscarriage POCs and frequently observed in preimplantation embryos, but is currently unappreciated by conventional single-site cytogenetic investigations. STUDY FUNDING/COMPETING INTEREST(S): This work was supported partly by Research Grant Council Collaborative Research Fund (C4062-21GF to K.W.C), Science and Technology Projects in Guangzhou (202102010005 to K.W.C), Guangdong-Hong Kong Technology Cooperation Funding Scheme (TCFS), Innovation and Technology Fund (GHP/117/19GD to K.W.C), HKOG Direct Grant (2019.050 to J.P.W.C), and Hong Kong Health and Medical Research Fund (05160406 to J.P.W.C). The authors have no competing interests to declare. TRIAL REGISTRATION NUMBER: N/A.

8 March 2026 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
YWYike Wang
Yike Wang
JZJinxiu Zhang
Jinxiu Zhang
DWDacheng Wang
Dacheng Wang
YZYuying Zhang
Yuying Zhang
LGLiping Gu
Liping Gu
YXYuhan Xing
Yuhan Xing

1 March 2019 in Fertility & Reproduction
Verified
Journal Article
Open access
PDF file
QYQueenie Yeung
Queenie Yeung
YZYing Xin Zhang
Ying Xin Zhang
PCPui Wah Jacqueline Chung
Pui Wah Jacqueline Chung
YKYvonne K.Y. Kwok
Yvonne K.Y. Kwok
BGBaoheng Gui
Baoheng Gui
TLTin-chiu Li
Tin-chiu Li
Preimplantation genetic testing for aneuploidies (PGT-A) has been controversial in its application to improve reproductive success, reduce time-to-pregnancy, and serve the intention-to-treat. Nevertheless, many in vitro fertilization (IVF) units have already introduced the service for one reason or another. Given PGT-A is not a stand-alone technique but a clinical service involving several disciplines, this mini review discussed the factors that can influence success rates when PGT-A is applied and highlighted practical issues encountered by clinicians, embryology, and genetics laboratories involved in the provision of PGT-A service.

19 May 2026 in Human Reproduction Open
Verified
Journal Article
Open access
YLYing Li
Ying Li
MCMatthew Hoi Kin Chau
Matthew Hoi Kin Chau
YZYing Xin Zhang
Ying Xin Zhang
BGBaoheng Gui
Baoheng Gui
WLWai Ting Lui
Wai Ting Lui
KCKwong Wai Choy
Kwong Wai Choy
STUDY QUESTION: What is the incidence of triploidy and genome-wide uniparental disomy (gwUPD) in human embryos currently undetected by conventional preimplantation genetic testing (PGT)? SUMMARY ANSWER: Triploidy and gwUPD were detected in 0.8% (8/1049) and 1.4% (15/1049) of blastocysts, respectively. WHAT IS KNOWN ALREADY: Concurrent PGT enhances embryo selection by simultaneously detecting monogenic disorders (PGT-M) or structural rearrangements (PGT-SR) and aneuploidy (PGT-A). However, triploidy and gwUPD, two genome-wide abnormalities causative of severe pregnancy outcomes, are not routinely detected by conventional PGT platforms and thus remain under-recognized at the preimplantation stage. STUDY DESIGN, SIZE, DURATION: This study consisted of three phases: Phase I validated the detection capability of PGT-Plus on cell lines with previously ascertained genetic abnormalities; Phase II performed retrospective clinical validation on leftover trophectoderm biopsy whole-genome amplification (WGA) samples, including 65 for PGT-M, 67 for PGT-SR, and 130 for PGT-A received during January 2019 and July 2023; and Phase III was prospective implementation of PGT-Plus under a diagnostic setting on 529 blastocysts received from August 2023 to June 2024. Additionally, a cohort consisting of 258 embryo transfers, previously ascertained as euploid by conventional PGT-A methods but associated with unfavorable outcomes, was retested by PGT-Plus, which identified previously undetected cases of gwUPD or triploidy. PARTICIPANTS/MATERIALS, SETTING, METHODS: In Phase I, cell lines with ascertained genetic abnormalities were tested using at least one of the following methods, including G-banded Karyotyping, quantitative fluorescence PCR (QF-PCR), chromosomal microarray analysis (CMA), and mate-pair sequencing. The previous results were compared with those from PGT-Plus. In Phase II, results from conventional PGT platforms were compared in parallel with PGT-Plus to evaluate its accuracy. Cell lines or real trophoblast biopsy samples from blastocysts were amplified by the multiple displacement amplification (MDA) method. PGT-Plus data analysis was performed in various dimensions. For PGT-A analysis, except for canonical read-count analysis to assess the genome dosage, single nucleotide polymorphism (SNP) analysis was also performed to identify triploidy and gwUPD. Furthermore, for families requesting PGT-M and PGT-SR, linkage analysis was carried out for haplotype construction in addition to read-count analysis and SNP analysis. In addition to prospective cohort of Phase III, a unique cohort with adverse reproductive outcomes after transfer of a ‘euploid’ embryo, as determined by conventional PGT-A platforms, was retested to identify any triploidy and UPD among these copy-number neutral embryos. The unfavorable outcomes included no pregnancy, biochemical pregnancy, miscarriage, and termination of pregnancy due to fetal anomaly. MAIN RESULTS AND THE ROLE OF CHANCE: PGT-Plus detected all abnormalities ascertained by prior platforms in Phases I and II. In total, triploidy and gwUPD were detected in 0.8% (8/1049) and 1.4% (15/1049) of blastocysts, respectively. Notably, 3.5% (9/258) of the unfavorable transfers of embryos previously classified as ‘euploid’ would have been prevented if triploidy and gwUPD were detected. In addition, 45.7% (12/35) of embryos previously classified as balanced by PGT-SR were translocation carriers. LIMITATIONS, REASONS FOR CAUTION: PGT-Plus, similar to other relative phasing methods, requires an additional family member for haplotype determination, although an embryo with a known genotype via prior independent testing is also acceptable. In addition, short-read next-generation sequencing (NGS) impedes the capacity of PGT-Plus to directly detect pathogenic SNVs located in highly repetitive regions of the genome, e.g. the HBA1 gene causative of thalassemia, which still require conventional methods, including short tandem repeats and PCR, to safeguard clinical diagnosis or can be addressed by long-read sequencing. WIDER IMPLICATIONS OF THE FINDINGS: This newly established PGT-Plus approach additionally detected gwUPD and triploidy in preimplantation embryos. It explained another 3.5% of ‘euploid’ embryo transfer failures. Meanwhile, embryo selection was enhanced by integrating PGT-M, PGT-SR, or PGT-A with an analysis of parental origin and stage of non-disjunction within a single PGT-Plus workflow. STUDY FUNDING/COMPETING INTEREST(S): This work was funded by the Research Grant Council Collaborative Research Fund (grant no. C4062-21GF to K.W.C.), the National Natural Science Foundation of China (grant no. 82502033 to Y.L.), and the Research Grant Council General Research Fund (grant no. 14100822 to J.P.W.C.). All authors declare that they have no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.